Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00397800 |
|
Recruitment Status : Unknown
Verified August 2012 by Technische Universität München.
Recruitment status was: Active, not recruiting
First Posted : November 10, 2006
Last Update Posted : August 28, 2012
|
Sponsor:
Technische Universität München
Information provided by (Responsible Party):
Technische Universität München
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Actual Primary Completion Date : | May 2008 |
| Estimated Study Completion Date : | May 2013 |